A study from the University of Cincinnati School of Medicine at the Annual Cancer Symposium on Surgical Oncology in Chicago on March 24, 2018 showed that adjuvant or additional treatment after surgical resection of rare types of gastrointestinal tumors does not improve patients ’ Survival rate. These findings provide in-depth insights into the treatment options for these types of cancer patients, and may no longer require prescribed adjuvant therapy, maintain quality of life, and save money.
In hoc studio inquisitores usi sunt tumorem scaenicorum I ad III aegros cum ampulla surgically ab 1998 ad 2006 remotis (5,298 aegris) in National Cancer Database Collegii chirurgorum Americanorum ad solam chirurgicam comparandam (3,785), chirurgicam plus aegroti. cum chemotherapy addito (316) et chirurgiae subeundae plus addito chemotherapy et radiotherapia (1,197) enucleatae sunt ad altiorem salutem.
29% (1,513) of patients who underwent surgical resection of ampullary similitudinem anorum received adjuvant therapy. Adjuvant therapy is more commonly used in patients with stage III, lymph node tumors, and positive surgical margins. However, there was no significant difference in stage-specific survival rates among patients with stage I, II, or III receiving any treatment. Similarly, patients with lymph node tumors and positive surgical margins received no adjuvant survival benefit. This national analysis showed that even for patients with aggressive disease, the adjuvant treatment of surgically removed ampullary tumors did not show any survival benefit.
Quocumque ergo genere cancri, quicunque cancer profecerit, necesse est subtypes cancri et earum differentias in gradu cellularum aestimare. Solum per probationem geneticam possumus determinare gradum hypotheticum patientium mutationes ac accuratiorem curationem dirigere. Multi suggestus atlas analysis Civitatum Americae Unitarum (cancrum auctoritatis medicamentorum societatis in Civitatibus Foederatis directum) non solum genesis cancer analysis in gradu genetico, sed etiam RNA et dapibus detectio coniungit ut multi-gradu machinae hypotheticae comprehendendo analyse notas tumoris aestimare, et medicamentum symptomaticum comprehende dirige. Plures informationes de Global Oncologist Network consuli possunt.
